Fermenta Biotec.
BSE: FERMENTA · Pharmaceuticals
Snapshot
Unlock Fermenta Biotec.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fermenta Biotech Limited is a specialised manufacturer and supplier of Vitamin D3, offering various forms including crystalline, resin, and cold water dispersible powders. The company operates primarily through its Chemicals/Bulk Drug segment, supported by a secondary property rental business.
Business Model
The company generates revenue by manufacturing and selling Vitamin D3 variants, enzymes, and bulk drugs for applications in pharmaceuticals, food fortification, and animal nutrition. Additionally, it earns rental income through its property segment.
Growth Outlook
Growth is driven by the increasing global demand for Vitamin D3 in food and beverage fortification and the expansion of pharmaceutical applications for its bulk drug portfolio.
Key Risks
- Regulatory Compliance. The company is subject to stringent global pharmaceutical manufacturing standards and health authority inspections.
- Raw Material Price Volatility. Fluctuations in the cost of key chemical inputs can significantly impact the profit margins of the bulk drug segment.
- Market Competition. The Vitamin D3 market is highly competitive, with pricing pressures from both domestic and international manufacturers.
- Foreign Exchange Risk. As an exporter of pharmaceutical ingredients, the company is exposed to volatility in currency exchange rates.
Start your research today
Unlock AI insights, financials, peers and live data on Fermenta Biotec. and 5,000+ companies — free.
Key Metrics
REVENUE
₹511 Cr
TTM · consolidated
NET PROFIT
₹58 Cr
TTM · consolidated
EPS
₹20.90
TTM · consolidated
RETURN ON EQUITY
15.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
22.2%
TTM · consolidated
P/E
26.5×
Q1 FY27 · consolidated
EV/EBITDA
13.7x
Q1 FY27 · consolidated
EBITDA MARGIN
21.1%
TTM · consolidated
NET PROFIT MARGIN
7.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Fermenta Biotec.FERMENTA | ₹1,399 Cr | 26.5× | 13.72 | -3.2% | 21.1% | 15.2% | 22.2% | +70.5% |
Anlon HealthcareAHCL | ₹1,578 Cr | 5.9× | 33.92 | — | 27.4% | 13.9% | 21.3% | -74.7% |
Jagsonpal Pharmaceuticals LimitedJAGSNPHARM | ₹1,485 Cr | 34.1× | 20.18 | 3.9% | 24.9% | 17.6% | 22.9% | +4.2% |
Amrutanjan Health Care LimitedAMRUTANJAN | ₹1,475 Cr | 27.5× | 16.18 | 10.7% | 17.7% | 15.5% | 20.2% | -28.1% |
KopranKOPRAN | ₹1,349 Cr | 54.6× | 23.66 | 12.0% | 9.1% | 4.8% | 7.7% | +60.6% |
Lincoln Pharmaceuticals LimitedLINCOLN | ₹1,209 Cr | 12.1× | 8.29 | 10.2% | 20.7% | 13.5% | 17.5% | +9.4% |
As of Q1 FY27
Financials
Fermenta Biotec.
BSE: FERMENTA · Pharmaceuticals
Snapshot
Unlock Fermenta Biotec.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fermenta Biotech Limited is a specialised manufacturer and supplier of Vitamin D3, offering various forms including crystalline, resin, and cold water dispersible powders. The company operates primarily through its Chemicals/Bulk Drug segment, supported by a secondary property rental business.
Business Model
The company generates revenue by manufacturing and selling Vitamin D3 variants, enzymes, and bulk drugs for applications in pharmaceuticals, food fortification, and animal nutrition. Additionally, it earns rental income through its property segment.
Growth Outlook
Growth is driven by the increasing global demand for Vitamin D3 in food and beverage fortification and the expansion of pharmaceutical applications for its bulk drug portfolio.
Key Risks
- Regulatory Compliance. The company is subject to stringent global pharmaceutical manufacturing standards and health authority inspections.
- Raw Material Price Volatility. Fluctuations in the cost of key chemical inputs can significantly impact the profit margins of the bulk drug segment.
- Market Competition. The Vitamin D3 market is highly competitive, with pricing pressures from both domestic and international manufacturers.
- Foreign Exchange Risk. As an exporter of pharmaceutical ingredients, the company is exposed to volatility in currency exchange rates.
Start your research today
Unlock AI insights, financials, peers and live data on Fermenta Biotec. and 5,000+ companies — free.
Key Metrics
REVENUE
₹511 Cr
TTM · consolidated
NET PROFIT
₹58 Cr
TTM · consolidated
EPS
₹20.90
TTM · consolidated
RETURN ON EQUITY
15.2%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
22.2%
TTM · consolidated
P/E
26.5x
Q1 FY27 · consolidated
EV/EBITDA
13.7x
Q1 FY27 · consolidated
EBITDA MARGIN
21.1%
TTM · consolidated
NET PROFIT MARGIN
7.8%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.3x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27